clinical trialBiotech

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (NCT04697576)

updatedDate Venue ClinicalTrials.gov

Source-permitted summary

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | Phase: PHASE1 | Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8

SourceClinicalTrials.gov

Verified by AISci

Public source attached

Source status for this paper in the current AISci reviewed snapshot.

Primary source
ClinicalTrials.gov
Correction status
none
Evidence coverage
1 sources / 1 publishers
Last metadata check
Jul 19, 2026
Open primary source

AI Reading Notes

Core signal

Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.

Core signal
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | Phase: PHASE1 | Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
Field context
Protein and Drug Design
People and labs
Not stated in the reviewed source.
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
Limits to check
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

Publication facts

Type
clinical trialSourceClinicalTrials.gov
Date
Jul 13, 2026SourceClinicalTrials.gov
Venue
ClinicalTrials.govSourceClinicalTrials.gov

External IDs

Author order

No reviewed author edge is attached to this output.

Organizations

No source-confirmed author affiliation is attached.

Related events

Topics

Relationship evidence

Timeline

  1. clinical trialIntralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma